Business
Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting
-Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell
About this update from Precision Biosciences, Inc.
[{"type":"text","content":"-Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia-\n -Abstract summarizes early results from first three patients with advanced NHL treated with PBCAR0191 at Dose Level 1 as of August 1, 2019- -No serious adverse events or dose-limiting toxicities observed over median 60 days follow-up. Two of three patients experienced objective tumor responses by Lugano criteria, with the third patient having evidence of anti-tumor activity- -Trial is ongoing and updated data, including from patients treated at Dose Level 2, will be presented during the ASH Annual Meeting- -Precision BioSciences to host investigator update event during ASH to discuss these data, starting at 8:15 p.m. ET on December 9, with live webcast available online- DURHAM, N.C., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that initial results from the ongoing Phase 1/2a trial of its lead investigational off-the-shelf (allogeneic) chimeric antigen receptor (CAR) T cell therapy candidate, PBCAR0191, will be presented during the 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, December 7-10, 2019. PBCAR0191 is Precision’s first allogeneic CAR T therapy candidate in clinical trials and targets the well characterized cancer cell surface protein CD19. It is being developed in collaboration with Servier, an international pharmaceutical company. The Phase 1/2a trial includes adult patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). The abstract outlining initial data from patients treated with PBCAR0191 at Dose Level 1 is available on the ASH conference website (https://www.hematology.org/Annual-Meeting/Abstracts). This trial is ongoing and updated results, including from patients treated at Dose Level 2, will be presented at the ASH Annual Meeting on December 9, 2019 starting at 6:00 p.m. ET. “We are excited to share initial clinical data from Precision’s PBCAR0191 program at ASH, which we believe demonstrate the potential of our differentiated approach ...